10 million people are diagnosed with Parkinson’s today and it is the fastest growing neurodegenerative disease.
Every 9 minutes, someone in the U.S. is diagnosed with Parkinson’s disease. 20% are younger than 64.
$ 52 billion in direct and indirect cost are associated with Parkinson’s in the U.S. yearly.
Most people with Parkinson’s (PwP) are underserved.
There is no cure today.
What is NeuroPath?
NeuroPath is a very comprehensive, patient-centric application and a digital platform to improve quality of life and increase treatment efficacy.
Who is NeuroPath for?
People with Parkinson’s, their caregivers, and their healthcare professionals.
How does it work?
PwP and caregivers report health data through our active and passive NeuroPath Insights and NeuroPath Navigator application.
These data are analyzed and categorized to provide insights.
It monitors patients remotely and supports daily treatment through remote therapeutics in-between consultations.
Clinicians can consult and interact with the PwP on the platform.
It alerts clinicians for risk and clinical improvement opportunities.
Why is NeuroPath different?
At NeuroPath, we believe that our success hinges on the tangible benefits of a patient-centric solution that becomes an indispensable part of their daily lives, extending its reach to encompass their whole care team.
What sets us apart from the rest is our steadfast dedication to empowering our users with the information they provide and desperately seek.
NeuroPath is not just another solution; it is a transformative force that places the power of information and support directly in the hands of those who need it most.
Join us on our journey to integrated Parkinson's care.
Changing the care path: Pro-active, Personalized, Predictive
Control therapy adherence Measure care path efficacy
Integrated care Apply value-based care programs
Public or Private Payers
Improve outcomes Reduce costs
Pharma or CRO
Measure drug efficacy Reduce clinical trial costs
For People with Parkinson's
+7,42 Quality Adjusted Life Years
Cost reduction up to 64% versus current care path
Additional revenue from reimbursements
for Public Health
Total Economic Value from slowing progression ranging from $36k to $442k per PwP
* An Economic Model of Parkinson’s Disease: Implications for Slowing Progression in the United States (Johnson et al, 2013)
NHS Right Care Scenario Sarah’s story
Benjamin Franklin espoused the idea that one can be financially successful while making the world a better place, an idea now known as the oft-quoted “doing well by doing good.“
Calling all potential investors, industry partners, and associations!
NeuroPath invites you to join us in revolutionizing Parkinson's care.
Together, we can make a significant impact.
Contact us today to explore investment, collaboration, and partnership opportunities: